Principal Investigator
Lynn Feun
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20231030
Clinical Trial Summary
A Phase 1/2 Exploratory Study of the TBL1 Inhibitor, Tegavivint (BC2059), in Patients With Advanced Hepatocellular Carcinoma
Phase
Phase I/II
Funding Agency/Sponsor
Industrial
Disease
Colorectal Cancer
Contact Information
Phone Number
305-243-2647